title: Infliximab (Remicade) and increased incidence of development of basal cell carcinoma.
abstract: Immunosuppression is a known risk factor for the development of non-melanoma skin cancers (NMSC). Certain medications that induce immunosuppression, such as tumor necrosis factor-α (TNF-α) inhibitors, are being used more frequently. We report a case of a young, pregnant woman who was treated with infliximab for Crohn's disease, and subsequently experienced a rapid growth of two pre-existing basal cell carcinomas. As use of TNF-α inhibitors increases, it is important to closely monitor patients for the development of NMSC.
authors.affiliation: SUNY Downstate Department of Dermatology, Brooklyn, NY, USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Gaines-Cardone
authors.forename: Elizabeth K
authors.initials: EK
authors.lastname: Hale
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000209:etiology* / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D011247:Pregnancy; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab